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Abstract
Since their identification in 1994, cancer stem cells (CSCs) have been objects of intensive study. 
Their properties and mechanisms of formation have together become a major focus of current 
cancer research, in part because of their enhanced ability to initiate and fuel tumor growth and 
their intrinsic resistance to conventional therapeutics. The discovery that activation in carcinoma 
cells of the epithelial-to-mesenchymal transition (EMT) program can give rise to cells with stem-
like properties has provided one possible mechanism explaining how CSCs arise and presented a 
possible avenue for their therapeutic manipulation. This review addresses the more recent 
developments in CSC research, focusing on carcinomas that are able to undergo an EMT. We 
discuss the signaling pathways that create these cells, cell-intrinsic mechanisms that could be 
exploited for their selective elimination or induction of their differentiation, and the role of the 
tumor microenvironment in sustaining them. Finally, we propose ways to exploit our current 
knowledge of their complex biology to design novel therapies to eliminate them.
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The Cancer Stem Cell paradigm
A semantic dispute?
The cancer stem cell (CSC) hypothesis posits the existence of subpopulations of neoplastic 
cells within a tumor that exhibit an elevated ability to seed new tumors upon experimental 
implantation in appropriate animal hosts. Implicit in this power is the ability of such cells to 
divide asymmetrically, yielding daughters that remain as CSCs (the trait of self-renewal) as 
well as daughters that differentiate into the neoplastic cells forming the bulk of the tumor. 
The reference to this notion as a hypothesis stems from the early days of CSC research, 
when their existence was the object of skepticism and intense debate. However, in light of a 
large body of supporting research reported in recent years, the existence of multiple 
subpopulations within a tumor with distinct tumor-initiating powers is no longer a matter of 
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speculation and hypothesis. Accordingly, the use of the term “cancer stem cell paradigm” 
now seems to be more appropriate (see Box 1 for a brief history of CSC research).
Beyond debates about the existence of CSCs are yet others surrounding the terms used to 
describe these cells. Participants of The 2011 Working Conference on CSCs have outlined 
guidelines on how to define these cells depending on the biological system in which they are 
being studied1. Initially used by Edmund Beecher Wilson in 18962, the term “stem cell” has 
been associated with normal development for almost a century before its use in the context 
of cancer in the late 1980s3,4. The century-long use of the term “stem cell” in the context of 
normal embryonic and adult development precluded, in the minds of some, its use in other 
contexts, notably those associated with neoplasia. While normal stem cells (SCs) often 
exhibit an ability to differentiate into multiple distinct cell types, to date most CSCs are not 
known to differentiate into more than a single cell type – the cells composing the bulk of the 
tumor. However, evidence for multilineage differentiation potential of CSCs has been 
reported in colon carcinomas and leukemias5,6, providing further basis for their residence at 
the apex of a hierarchy and possessing core traits of self-renewal and differentiation, as do 
normal SCs.
While the phenotypes of normal stem cells seem to be fixed and therefore easier to identify, 
the phenotypes of CSCs are complex, variable from one tumor to another, and often affected 
by the abnormalities resulting from the process of neoplastic transformation; hence CSCs 
are often difficult to rigorously define by associating them with traits beyond their shared 
functional trait of tumor-initiating ability. Moreover, the existence of CSCs within tumors 
implies that cancer cells sharing a common genetic make-up can nevertheless exist in at 
least two alternative phenotypic states – CSCs and non-CSCs.
Intra-tumoral heterogeneity and CSCs – two sides to the same coin?
The existence of several forms of intra-tumoral heterogeneity has been discussed in detail 
elsewhere 7. Taking breast cancer as an example, exome and whole-genome sequencing 
efforts have shown that majority of these tumors have more than one driver mutation, with a 
large proportion of abnormalities affecting so-called passenger genes 8. The presence of 
such a large number of genetic abnormalities could lead to the occurrence of different 
subpopulations within the tumor, each of these possessing different combinations of 
genetically derived predispositions for growth, survival and dominance in the tumor 
microenvironment. Moreover, single-cell sequencing has enabled the identification of 
distinct subpopulations within human breast cancer samples, identifying one of these as the 
dominant, metastasis-seeding population 9. In addition to the contributions to intratumoral 
heterogeneity of genetic alterations, cancer cells also carry heritable epigenetic alterations, 
which may serve equally well to generate phenotypically distinct subpopulations within 
tumors.
The existence of CSCs represents an entirely distinct dimension of intratumoral 
heterogeneity. Thus, each of the above-described subpopulations of carcinoma cells within a 
tumor may carry its own group of CSCs. By definition, the CSCs and non-CSCs within such 
a subpopulation will share the heritable genetic and epigenetic alterations that define that 
subpopulation. With the advent of new technologies, this form of heterogeneity is now more 
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accessible to scientific inquiry, but the causes and effects of non-genetic heterogeneity are 
still poorly understood. A more comprehensive review of intratumoral heterogeneity and 
cancer stem cells has been published recently 10.
Properties of CSCs
Markers used for CSC isolation
CSCs have been identified in a variety of carcinomas in various frequencies using 
combinations of cell-surface antigens. Indeed, the ability to use cell-surface markers to 
physically isolate distinct subpopulations of neoplastic cells with differing biological 
properties represents the most compelling demonstration that cancer cells can reside in 
multiple, alternative phenotypic states within a given tumor. Of note, several cell-surface 
markers used for the isolation of CSCs represent cell-surface antigens expressed by normal 
adult stem cells e.g., the CD133 antigen has been used as a CSC marker in various cancers, 
including those of the brain11, lung12, pancreatic13 and prostate14 among others, while also 
being a reliable marker of stem/progenitor cells in normal adult tissues, such as the brain15, 
kidney16, liver17 and prostate18. Thus, earlier studies of normal tissues uncovered a series of 
these antigens that subsequently proved useful for segregating CSCs from non-CSCs within 
tumors.
In addition to such cell-surface markers, certain intracellular proteins have also been useful 
for studying normal and cancer SCs. Aldehyde Dehydrogenase I (ALDH1) is a protein that 
has been used to mark CSCs in several cancers including leukemias19, carcinomas of the 
breast20, colon21, liver22, lung23 and pancreas24, among others. The “side population” (SP) 
that is capable of efflux of the Hoechst 33342 dye represents another non-cell-surface 
marker that has been used for the isolation of normal and cancer SCs25–27. The most 
commonly used markers and marker combinations are summarized in Table 1.
The similarity of antigen display by normal tissue SCs and the CSCs from corresponding 
neoplastic tissues would seem to lend further support to the notion that CSCs are, at least in 
certain respects, bona fide SCs. In the eyes of some, this would seem to indicate that CSCs 
derive directly from the SCs in the normal tissue-of-origin of a tumor. However, as 
discussed in Box 2, alternative hypotheses describing the origins of CSCs must also to be 
entertained.
Despite the growing list of CSC markers, several of these have been reported not to be 
uniformly useful in identifying CSCs. For example, although the CD44+CD24− profile was 
used in early studies of breast CSCs, the authors report that not all breast cancer cell 
populations could be stratified using this set of markers28. In fact, several of these markers, 
including CD44, CD90 and CD34, play roles in cell adhesion and attachment and have been 
thought to favor the survival of cells in the relatively harsh environment of immunodeficient 
mice, arguing that the procedure of xenotransplantation may inadvertently select for the 
outgrowth of cells expressing these cell-surface proteins29. This might suggest that, in the 
long run, it may be more profitable to employ markers that function physiologically to 
support the CSC phenotype, thereby ensuring close linkage between marker display and 
residence in the CSC state. For instance, components of the signaling pathways that play an 
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essential role in the biology of colorectal CSCs, such as that driven by canonical Wnt 
signalling, may eventually yield highly specific and thus highly useful CSC markers30. A 
more detailed discussion of CSC markers has been recently published31.
Epithelial-to-mesenchymal transition and the stem-cell state
The cell-biological program termed the epithelial-mesenchymal transition (EMT) was 
initially studied because of the critical roles that it plays in many of the cell-type 
interconversions underlying organogenesis during normal development. During passage 
through an EMT, epithelial cells lose their differentiated characteristics of cell-cell adhesion 
and lack of motility and acquire instead the traits of mesenchymal cells that confer on them 
migratory and invasive powers along with elevated resistance to apoptosis32. In the context 
of carcinoma pathogenesis, the EMT has been increasingly linked to the ability of carcinoma 
cells to invade locally and disseminate to distant anatomical sites, where they may then 
initiate metastases33.
In general, activation of an EMT program in both normal and neoplastic cells appears to 
require heterotypic signaling between these cells and neighboring stromal cells. Thus, 
stromal signals, largely in the form of secreted factors, are released by various stromal cell 
types and impinge on nearby epithelial cells, resulting in the induction of intracellular 
signaling cascades in the latter. These pathways lead to the expression of transcription 
factors (TFs) that orchestrate the EMT program (EMT-TFs) and regulate various target 
genes whose expression ultimately results in acquisition of mesenchymal cell traits.
Evidence that the EMT process contributes to the progression of a variety of carcinoma 
types is rapidly accumulating from diverse laboratories34–38. The EMT program has also 
been shown to result in the generation of epithelial cells that have stem-like properties 39, 40. 
This appears to be true for both normal and neoplastic mammary epithelial stem cells, the 
latter representing cells that exhibit CSC-like properties39,40. Indeed, currently available 
evidence is compatible with the notion that epithelial cells in the normal mammary gland 
employ components of the EMT program as the main route for entering into the SC state41. 
It remains to be seen whether other epithelial tissues rely similarly on versions of the EMT 
program to generate their own normal and, by extension, neoplastic SCs. It appears that, 
depending on the EMT-TFs involved, epithelial cells may enter into the SC state, the 
mesenchymal state, or both. Moreover, while not yet reported, accumulating evidence 
suggests that normal and neoplastic SCs arising in epithelial tissues generally exhibit a 
mixture of epithelial and mesenchymal traits, indicating that they have advanced only 
partially through an EMT program, as discussed in more detail below41.
Signaling pathways characteristic of EMT-induced CSCs
Since the EMT is a key program generating CSCs, it has become important to elucidate the 
signaling pathways responsible for activation of this program and for maintenance of cells in 
the resulting mesenchymal (or quasi-mesenchymal) state. As mentioned, in the case of 
carcinomas, the EMT is often and perhaps invariably induced through the convergence of 
various signals deriving from the tumor stroma, including extracellular matrix components 
such as collagen, as well as secreted factors, such as TGF-β, canonical and non-canonical 
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Wnts42. Such signalling cascades induce expression of the EMT-TFs mentioned above, 
which include members of the Snail, Twist and Zeb family of proteins, among others. These 
proteins, acting as transcription factors, are responsible for orchestrating the gene expression 
programs that activate effectors of EMT phenotype, doing so through the repression of 
epithelial genes and the activation of mesenchymal genes.
The TGF-β pathway is the first and best-studied signalling cascade operating to induce the 
EMT program in various epithelial tissue types43. Binding of TGF-β ligand induces 
dimerization of the types I and II TGF-β receptors, leading in turn to the phosphorylation of 
Smad2 and Smad3, which form a complex with Smad4; once formed, the resulting 
transcription factor complex migrates to the nucleus, where it can induce, among other 
responses, a transcriptional program that mediates the acquisition of mesenchymal 
properties and suppression of epithelial traits43. In the context of cancer, this canonical 
TGF-β pathway is also known to collaborate with several other pathways including ERK44, 
p38 MAP Kinase45, Wnt-β-catenin46 and PI3 kinase47 in promoting mesenchymal and 
migratory properties of cancer cells. Similarly, both canonical and non-canonical types of 
Wnt signaling are responsible for induction of an EMT and stem-like properties in various 
tissue types48–50.
Recent studies have unveiled a novel collaboration between the aforementioned pathways in 
the induction of an EMT; this signalling operates through paracrine signals originating 
ostensibly in the tumor stroma as well as autocrine signals derived from the carcinoma cells 
themselves50. Thus, the paracrine signals trigger expression of an EMT program in 
carcinoma cells, which is subsequently maintained by autocrine signals generated by these 
neoplastic cells. Such autocrine signals, at least in one case examined, involve the same 
signalling factors that previously triggered initiation of the EMT program. Stated differently, 
these autocrine signals serve to maintain the resulting mesenchymal state in a self-
perpetuating fashion in the absence of further extrinsic signals coming from the stroma; such 
persistent signalling would seem to assist individual tumor cells to migrate and invade 
through foreign tissue while maintaining, in a cell-autonomous fashion their EMT-
associated traits; in the longer term, these wandering cells may disseminate to distant sites in 
the body, i.e., metastasize. Consistent with this notion, recent studies of the circulating 
tumor cells (CTCs) released by primary carcinomas have shown expression of the WNT2 
gene whose product increases propensity for metastasis37.
Autocrine signaling loops may also serve an alternative function: to perpetuate residence of 
cells in the epithelial state. For example, the autocrine production by epithelial cells of bone 
morphogenetic proteins (BMPs), Gremlin, DKK1 and SFRP serve as inhibitors of autocrine 
TGF-β and Wnt signalling respectively, protecting the epithelial cells from inadvertent 
activation of signalling that would lead to activation of the EMT program; conversely, the 
shutdown of these secreted inhibitors in mesenchymal cells opens the door to autocrine 
TGF-β and Wnt signaling, permitting activation of mesenchymal gene expression programs. 
Given the apparent close connection between the EMT program and the CSC state, these 
same dynamics would seem to apply as well to entrance into and out of this phenotypic 
state. Other signalling pathways that are implicated in the induction and maintenance of 
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CSC traits include Prostaglandin E251, Hedgehog52, NOTCH53 and PDGFR54; a summary 
of these pathways is presented on Figure 2.
The interplay between such autocrine signals produced by carcinoma cells and paracrine 
signals arising in the tumor stroma presumably creates a complex array of cues that dictate 
the extent of epithelial/non-CSC and mesenchymal/CSC characteristics displayed by 
carcinoma cells. The possibility that these signals can function in an essentially unlimited 
number of combinations implies the existence of multiple distinct phenotypic states between 
the fully differentiated, strictly epithelial state and the fully mesenchymal state, these two 
states representing the extremes of the EMT program.
In truth, the extent of epithelial vs. mesenchymal polarization that carcinoma cells undergo 
within actual human tumors is poorly resolved at present. It seems increasingly likely that 
carcinoma cells that have activated an EMT program usually enter into a state in which 
certain epithelial markers are retained while mesenchymal are newly acquired, resulting in 
what is often termed a “partial EMT”. Accordingly, cells that have passed entirely through 
an EMT program and have thus undergone a “complete EMT” resemble transdifferentiated 
cells of the mesenchymal mesodermal lineage and lose the epithelial vs. mesenchymal 
plasticity that is required for expression of tumor-initiating properties and is created by a 
partial EMT55,56. Moreover, bona fide epithelial SCs – both normal and neoplastic – would 
seem to arise from cells that have such mixed epithelial/mesenchymal properties.
Resistance to conventional drugs
Chemotherapy and radiotherapy have been the treatments of choice for the past half-century, 
often affording remarkable reductions in tumor burden. As mentioned in passing earlier, 
induction of an EMT leads to the acquisition of resistance to both forms of therapy, a 
phenomenon that has been documented in the greatest detail in breast and ovarian 
cancers57, 58. Chemoresistance has also been shown to be higher in tumors that harbor a 
gene signature indicative of desmoplastic or reactive stroma, which is consistent with the 
notion that signals secreted by a reactive stroma play a major role in the induction of an 
EMT59. In light of the complex regulation of the CSC state and its maintenance, how might 
one utilize our current knowledge of signal transduction biochemistry to specifically target 
this treatment-resistant subpopulation?
At present, we possess only an incomplete understanding of the actual biochemical and cell-
physiologic mechanisms underlying the intrinsic chemo- and radioresistance of tumor cells 
that have passed, even partially, through an EMT. Moreover, resistance to cytotoxic 
treatments may also be attributable to the lower proliferative rate that results from the 
acquisition of mesenchymal properties60,61. Indeed, CSCs from a variety of tumors have 
been shown to be slow cycling and to exhibit an increased level of quiescence compared to 
the majority populations of cancer cells within certain tumors62,63. Additionally, the 
resistance to chemotherapy in normal stem cells has been attributed to high-level expression 
of anti-apoptotic proteins64 and to ABC transporters that are capable of efflux of the 
Hoechst 33342 dye, creating the “side population (SP)” observed upon fluorescence-
activated cell sorting (FACS) fractionation of tumor cell populations25,65,66; these 
mechanisms could also operate to confer similar properties on CSCs.
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A recent study using a genetically engineered mouse model (GEMM) of glioblastoma 
development has shown that a quiescent, population of tumor cells survives treatment with 
temozolomide and regenerates the tumor by differentiating into populations of highly 
proliferative cells37. This finding demonstrates directly that the CSCs in this tumor exhibit 
elevated resistance to chemotherapy, and that purely cytotoxic treatment regimens that target 
cycling cells are bound to fail unless accompanied by a targeted therapy that specifically 
targets these small, phenotypically distinct subpopulations.
Therapeutic Targeting of CSCs – what has been done so far?
Understanding of CSC-dependent signaling pathways
The identification and characterization of CSCs has revealed the need for specific molecular 
therapies that target the key signalling pathways supporting these cells and their residence in 
the CSC state. As described above, CSCs and normal SCs share a number of properties. This 
explains why signalling pathways, such as those activated by Wnt, TGF-β, NOTCH and 
Hedgehog – all known to be essential for the self-renewal properties of normal adult stem 
cells 52, 53, 67, 68 – are emerging as attractive targets whose inactivation may allow 
elimination of CSCs,
Studies of CSCs and the EMT program have led to a preliminary understanding of the 
signaling pathways that these cells preferentially employ, examples of which are illustrated 
in Fig 2. From these studies it has become evident that these pathways are highly context-
dependent and several of them may actively collaborate to maintain residence in the CSC 
state, one example being the aforementioned activation of both TGF-β and Wnt signalling 
pathways in the maintenance of mammary CSCs50. These extracellular signalling channels 
may offer opportunities for interdicting these pathways in the extracellular space through, 
for example, neutralizing antibodies.
Screens to identify novel targeted therapeutics
Pharmacology has been profoundly changed by the ability to screen large, complex chemical 
compound libraries in order to identify chemical species that target specific proteins within 
cells. In the case of CSCs, chemical screening for agents that specifically target these cells 
has been a challenge due to their rarity and the inability to propagate in culture CSC 
populations isolated by flow cytometry. One strategy to circumvent this hurdle has involved 
the recent screening of mammary epithelial cells that have been forced experimentally to 
undergo an EMT and thus have acquired certain CSC characteristics, including increased 
tumor-initiating ability in vivo39, 40.
One group has carried out a 16,000-compound library screen in order to identify compounds 
that could preferentially kill EMT-induced CSCs; these CSCs were derived through 
knockdown of E-cadherin, an alteration known to favour activation of the EMT program57. 
Through this screen, this group showed that salinomycin pretreatment of CSCs resulted in a 
~100-fold decrease in tumor-seeding ability relative to the conventional agent, paclitaxel. 
Similar screens have subsequently been carried out by others to identify compounds that 
preferentially target glioblastoma CSCs69, ovarian CSCs70, breast CSCs71 and AML 
LSCs72.
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In principle, such screens can allow the identification of novel modulators of cell phenotype 
and do so in an unbiased way. However, these studies also bring to light the still-incomplete 
understanding that we possess of CSCs and the pathways that these cells depend on. Like 
other similar strategies of drug development, such screens should be used as starting points 
for further functional studies that reveal at a mechanistic level precisely how these agents 
actually work. Additionally, screens like these are carried out in two-dimensional cultures in 
the absence of components that would ordinarily be present in the tumor microenvironment 
e.g., the extracellular matrix, stromal cells including fibroblasts, myofibroblasts and immune 
cells, as well as endothelial cells forming microvessels. Such deficiencies must be taken into 
account when attempting to extrapolate the results of these screens to the behaviour of CSCs 
in vivo.
Ideally a future anti-CSC therapy, using agents such as those cited above, should eliminate 
the pool of cancer cells that are intrinsically resistant to conventional therapies, while a 
concomitantly administered conventional agent would eliminate the non-CSC cells, which 
are known to be susceptible to existing cytotoxic therapies. Importantly, elimination of the 
CSCs on its own may not suffice to induce an acceptable, durable clinical response, since 
new CSCs may be generated in CSC-depleted tumors via the spontaneous dedifferentiation 
of non-CSCs – a consequence of cellular plasticity that enables the emergence of de novo 
CSCs from differentiated cells73, 74.
Therapeutic targeting of CSCs – other strategies and the road ahead
Targeting the tumor microenvironment
Direct targeting of CSCs represents one major strategy for eliminating these cells and thus 
the tumors that they support. However, alternative strategies have been suggested by the 
rapidly growing information on the tumor microenvironment and its role in triggering 
activation of an EMT program in carcinoma cells and possible entrance of these cells into 
the CSC state. As mentioned above, heterotypic signals arising in the tumor-associated 
stroma are often responsible for activating this program in nearby carcinoma cells. 
Prominent among the signal-emitting cells of the stroma are fibroblasts, myofibroblasts, 
adipocytes and mesenchymal stem cells (MSCs), infiltrating immune cells such as 
macrophages and neutrophils, as well as endothelial cells that make up the walls of blood 
vessels that extend through the tumor (See Fig 3; Box 3). Detailed reviews of these stromal 
components have been published previously75, 76. In addition, the extracellular matrix 
(ECM) assembled by these cells also has strong effects on invading carcinoma cells 77.
In the case of colon carcinomas, the interactions between the carcinoma cells and stromal 
cells, specifically myofibroblasts, have been shown to be important in inducing and 
maintaining a more stem-like state in the former30, showing directly that the stroma can play 
a major role in the generation of CSCs. Moreover, interactions between certain classes of 
carcinoma cells and MSCs induce the latter to secrete Prostaglandin E2 (PGE2), which is 
then responsible for the activation of the β-catenin signaling in the carcinoma cells; once 
activated, this signaling promote their acquisition of a CSC-phenotype78. Similar reciprocal 
interactions also exist in breast cancers, where MSCs recruited from the bone marrow 
interact with carcinoma cells via paracrine cytokine signalling involving CXCL7 and IL-6, 
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which are responsible for stimulating the self-renewal of the neoplastic cells79. Hence, 
MSCs secrete cytokines and growth factors that together create a suitable niche enabling 
carcinoma cells to acquire and maintain stemness. Similar roles have also been reported for 
tumor-associated macrophages (TAMs), which secrete factors such as IL-6 that activate the 
JAK-STAT pathway within the tumor cells, enhancing their tumorigenicity and resistance to 
chemotherapy by imparting CSC properties to them80–82.
In principle, the rapidly accumulating insights into the paracrine signaling pathways 
activating and sustaining the CSC program should provide insights for targeting CSCs; such 
a focused approach would represent an alternative to the untargeted use of high throughput 
screening described above. For example, one means of blocking pathways activated by 
stroma-derived signals could employ antagonists of the EP4 PGE2 receptor, such as the 
small molecule RQ-1598683, thereby reversing the tumor-promoting effects that MSCs have 
on carcinoma cells. Similarly, inhibitors of STAT3 DNA-binding, such as the small 
molecule NSC 7485984, may be effective in blocking immune cell-activated IL-6/STAT3 
signaling that supports CSC properties in certain carcinomas.
Of course, such approaches may also result in inhibition of signaling cascades in normal 
cells in which these signals play critical roles. For example, Wnt signaling, operating via 
intracellular β-catenin signaling, is known to be essential for the regulation and homeostasis 
of intestinal stem cells85, 86, and the use of Wnt inhibitors might therefore lead to a depletion 
of the normal resident stem cell population that is responsible for continuous regeneration of 
the intestinal epithelium. However, the dependency of colorectal CSCs on β-catenin 
signaling might exceed that of the normal intestinal stem cells, yielding a favorable 
therapeutic index, such that a low dose treatment might still be able to deplete CSC activity 
without significantly affecting normal organ homeostasis. Indeed, several clinical trials 
using inhibitors of Wnt signaling are currently underway, such as a currently ongoing phase 
I study of an oral inhibitor of Porcupine (LGK974), an enzyme involved in the post-
translational maturation of Wnt proteins, for treating patients with advanced breast and 
pancreatic cancer (http://clinicaltrials.gov/ct2/show/study/NCT01351103).
An alternative approach to disrupting stromal signals might involve preventing the cellular 
sources of these signals from being recruited into the tumor stroma in the first place. Thus, 
MSCs are often recruited into the tumor-associated stroma by carcinoma cell-derived IL-887. 
In such cases, inhibition of this homing signal might be effective in preventing MSC 
localizing to the tumor stroma and the resulting development of a supportive CSC niche. 
Similar tropic signals have also been reported for macrophages, which home to the primary 
tumor in response to factors such as CSF-1 and several chemokines, including CCL2, CCL5 
and CXCL1288–90. Antibodies that block the CSF-1 receptor (CSF1R) have been developed 
and shown to be effective at reducing the numbers of tumor-associated macrophages homing 
to tumors in syngeneic mouse tumor models91. Similarly, inhibitors of the tyrosine kinase 
activity of CSF1R have also been developed and shown to inhibit the tumor-promoting 
effects of macrophages, including the acquired resistance of tumor cells to chemotherapy92. 
A CSF1R kinase inhibitor, the small molecule ARRY-382, has recently gone through phase 
I clinical trials in patients with metastatic cancers (http://clinicaltrials.gov/ct2/show/
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NCT01316822) and may be the forerunner of a large repertoire of agents that are used either 
singly or in combination with other drugs to prevent macrophage homing.
Inhibition of CSC-dependent pathways
One strategy to block the initiation of the EMT program as well as entrance into and 
maintenance of the CSC state has already been suggested by findings cited earlier. Thus, 
epithelial non-CSCs cells synthesize and secrete high levels of physiologic inhibitors of Wnt 
signaling, such as SFRP and DKK proteins, which act at the cell surface to block ligand 
binding-mediated activation of Frizzled receptor signalling 50. As argued above, these 
secreted inhibitors ostensibly serve to reinforce residence in the epithelial state. Similarly, 
secreted inhibitors of the TGF-β pathway, including Gremlin and BMPs 4, 6, 7, 9, 10, are 
expressed and secreted at high levels in the non-CSCs, where they appear to block another 
pathway (involving TGF-β) that is critical for maintenance of the non-CSC/epithelial state50. 
Derivatives of these secreted inhibitory molecules, acting in the extracellular space, could 
become potential therapeutics that prevent stochastic inter-conversion between the CSCs 
and non-CSC states, tilting the balance in favour of the non-CSC state. We note that 
therapeutic proteins like these are difficult and expensive to produce in large quantities and 
often difficult to deliver into the interstices of complex tissues including tumors.
Given the importance of Wnt signaling for the induction of the CSC state, several low 
molecular weight inhibitors of this pathway have been developed. One of the first inhibitors 
to target the Wnt pathway was ICG-001, a small molecule that blocks the ability of CREB-
binding protein (CBP), a co-factor for a large number of transcription factors93, to act as a 
co-activator of the β-catenin-TCF complex, the transcription factor complex activated by 
canonical Wnt signalling 94. An inhibitor of the previously cited Porcupine enzyme (the 
small molecule IWP295 or LGK97496), a membrane-bound O-acyltransferase responsible 
for the post-translational maturation of Wnts via palmitoylation, has also been developed for 
the inhibition of the pathway. These inhibitors may be effective in preventing secretion of 
active Wnt molecules by the stromal cells, thereby blocking the paracrine signalling that 
triggers formation of new CSCs; in addition, they may block the autocrine signalling that is 
used by existing CSCs to maintain their residence in the SC state. Recent studies have also 
identified a role for yet another β-catenin co-factor, YAP1, which forms a complex β-catenin 
and is essential for the formation of β-catenin-driven cancers97. Reviews detailing the 
targeting of various aspects of the Wnt98 and TGF-β99 pathways have been published 
elsewhere.
Several molecules targeting various nodes of the Hedgehog and NOTCH pathways are also 
coming into prominence for their ability to target CSCs. For example, IPI926, a derivative of 
the natural product SMO antagonist cyclopamine100, is undergoing clinical trials for 
malignancies, such as basal cell carcinomas101 and metastatic pancreatic cancer, in 
combination with chemotherapeutic drugs such as gemcitabine (http://clinicaltrials.gov/
show/NCT01130142). Similar trials have also been initiated for the SMO competitive small 
molecule antagonist GDC-0449 against various tumors 102, 103, with FDA approval being 
granted to treat adults with advanced basal cell carcinoma. MK-0752, a small molecule 
gamma secretase inhibitor, is under clinical trials for the treatment of advanced solid 
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tumors104, whereas antibodies targeting Delta-like ligand 4 of NOTCH105 are also 
promising candidates to reduce CSC frequency of breast tumor xenografts and other solid 
tumors106. A list of inhibitors that target pathways that are preferentially utilized by CSCs 
and may possess therapeutic utility is summarized in Table 2. Unanswered by these studies 
are the therapeutic indices that these agents will exhibit, that is, will they in fact target 
neoplastic CSCs far more effectively than the SCs residing in corresponding normal tissues?
Differentiation therapy to curb stem-like properties of CSCs
Despite being intensively pursued for almost four decades, the search for ideal targeted anti-
cancer drugs has yielded relatively few successes. One of the first successes of targeted 
therapy for any type of cancer involved the use all-trans retinoic acid (ATRA), which was 
given to patients suffering from acute promyelocytic leukemia107. Following treatment with 
ATRA, leukemic promyelocytes are relieved of their block of differentiation and 
differentiate into mature granulocytes. The success of this therapy has led to the concept that 
differentiation therapy may be effectively used to treat other forms of cancer. In the case of 
CSCs, notably those in carcinomas, the notion would be to induce their exit from the CSC 
state into the more differentiated epithelial state of non-CSCs.
Other agents that have similarly been shown to be beneficial in differentiation therapy 
include (i) phorbol myristate acetate (PMA), which is capable of inducing leukemic cell 
differentiation by, among other pathways, protein kinase C (PKC)-mediated induction of 
transcription factors such as PU.1 and AP1108; (ii) hexamethylamine bisacetamide (HMBA), 
which induces differentiation of human leukemia cells through several distinct 
mechanisms109; (iii) dimethylsulfoxide (DMSO), which induces differentiation of human 
promyelocytic leukemias110; and (iv) vitamin D3 which induces maturation of several 
leukemic cell lines111.
Yet other compounds such as suberoylanilide hydroxamic acid (SAHA), a histone 
deacetylase inhibitor (HDACi), have been shown to induce differentiation of human breast 
cancer cells112 and endometrial carcinomas113. The inhibition of HDACs is thought to 
release the repression of gene promoters that play major roles in the processes of 
differentiation and cell cycle arrest, thereby permitting their expression. Another functional 
class of compounds that induce cell differentiation is represented by 5-azacytidine, a 
chemical analogue of cytidine, which acts by inactivating the DNA methyltransferases that 
catalyze methylation of CpG islands and associated transcriptional repression at gene 
promoters114.
The current explosion in the field of epigenetics research (defined here as the study of 
various types of chromatin modification) is uncovering a large number of histone 
methyltransferases and histone demethylases115. Modulation of these enzymes might also 
serve to increase the transcription of genes that are important for CSC differentiation or 
silence those that are required for cell migration and invasion. For example, the promoter of 
the CDH1 gene, which encodes E-cadherin, the keystone of the epithelial state, is a target of 
silencing in many cancers through the actions of the polycomb repressive complex (PRC2), 
which imposes the K27me3 repressive mark on histone H3116. Hence, inhibitors of histone-
modifying enzymes, such as the methyltransferase EZH2117, could act as differentiation-
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inducing agents of CSCs that have undergone an EMT, acting by inducing the re-expression 
of E-cadherin and thereby restoring epithelial properties. In fact, the small molecule EZH2 
inhibitor E7438 is currently under phase I/II clinical trials for advanced solid tumors and B-
cell lymphomas (http://clinicaltrials.gov/ct2/show/NCT01897571). A more detailed review 
of epigenetic regulation of EMT and CSCs has recently been published118.
All differentiation-inducing agents act on the premise that a block of terminal differentiation 
is one of the major characteristics of the neoplastic state. The realization of this phenomenon 
came from studying leukemias and analyzing the phenotypes of cancer cells in relation to 
the normal differentiation hierarchy of the hematopoietic system. Thus, acute myeloid 
leukemia caused by the MLL-AF9 chromosomal translocation leads to the expansion of 
leukemic stem cell populations that exhibit a cell-surface antigen profile similar to that of 
granulocyte-monocyte progenitors119. In the case of MLL-AF9 leukemias, it is known that 
cells are maintained in the less-differentiated progenitor stage by the fusion protein, which 
activates target genes such as HOXA9/MEIS1 that are responsible for coordinating a 
downstream CSC program through aberrant methylation of H3K79 by the histone 
methyltransferase DOT1L120. Hence, inhibitors of DOT1L may specifically act to disrupt 
the MLL-AF9-induced transcriptional program that fuels these cancers121.
Similar to an argument made earlier, a clinically effective differentiation therapy would need 
to be combined with chemotherapy in order to eradicate both CSC- and non-CSC 
populations within a tumor. In fact, more recent studies have focused on such combinations 
that involve inhibition of TGF-β, which results in differentiation of triple-negative breast 
cancer CSCs, in combination with paclitaxel, which should eradicate the rapidly cycling, 
non-CSCs forming the bulk of tumors under treatment122. Targeted therapy would 
presumably act by depleting CSC potential, giving rise to non-CSC counterparts that are 
more susceptible to chemotherapy. In fact, the use of agents that specifically target CSCs in 
combination with conventional chemotherapy has already been evaluated in clinical trials 
designed to gauge their efficacy in combination with radiotherapy for metastatic breast 
cancers (http://clinicaltrials.gov/ct2/show/NCT01401062).
One proviso must be cited here, suggested by observations that disseminated carcinoma cells 
must be able to undergo a mesenchymal-to-epithelial transition (MET) at their site of 
dissemination in order to generate the mixed CSC/non-CSC populations that appear to be 
critical to the robust growth of a tumor. 123, 124. Hence inducing CSC differentiation by 
inducing an MET, while still inhibiting CSC formation and maintenance in the primary 
tumor, may inadvertently support the process metastatic colonization at distant sites. The 
complex dynamics of these reversible processes operating during the invasion-metastasis 
cascade remain to be elucidated.
Directed immunotherapy against CSCs
The last decade has seen resurgence of the idea of directing the cancer patient’s immune 
system against tumor-specific and tumor-associated antigens. Strategies that exploit our 
understanding of the immune system for cancer therapy include the use of specific peptides 
that are derived from tumor antigens, which could be used for cancer vaccination as 
immunotherapy, the use of dendritic-cells as vaccines to activate adaptive immune cells 
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against specific antigens, and the blockade of immune checkpoints that inhibit anti-tumor 
immune responses125. T-cell responses to a particular antigen are dictated by the nature of 
their interaction with an antigen-presenting cell, and depend on co-stimulatory and inhibitors 
signals that are delivered upon the binding of specific ligands from antigen-presenting cells 
to complementary receptors on T-cells. The modulation of these so-called immune 
checkpoints through the use of antagonists of inhibitory signals has been recognized as a 
major avenue for the development of novel immune-based therapies 125. In fact, drugs such 
as Ipilimumab, a CTLA4-blocking antibody, have been found to confer clear benefit in 
treating melanoma 126, 127, with clinical trials underway for several other malignancies 
including prostate cancer (http://clinicaltrials.gov/ct2/show/NCT01194271) and ovarian 
cancer (http://clinicaltrials.gov/ct2/show/NCT01611558). Accordingly, the exploitation of 
the immune system may yield another dimension of anti-CSC therapy by directing 
immunocytes to recognize CSCs through the unique collection of cell-surface antigens that 
these cells display. We note, however, another process that may deflect immune attacks on 
tumors: the autocrine secretion of TGF-β (a known immunosuppressant) by CSCs may 
create zones around these cells that are protected from attack by various cellular components 
of the immune system50128. In addition, the CSC-secreted TGF-β may cause the formation 
of regulatory T cells (Tregs) that have additional immunosuppressive effects on other 
subclasses of T lymphocytes129.
As described earlier, the identification of CSC cell-surface markers (see Table 1) has 
enabled the isolation of these cells from primary tumors. Such markers could be used to 
survey tumor antigens that are preferentially expressed on the CSCs compared to the bulk of 
tumor cells and reveal novel vulnerabilities that could be exploited to design stem cell-
specific immunotherapies. Additionally, the expression levels of certain potentially 
inhibitory receptors that could attenuate an immune response could be higher in CSCs 
compared to non-CSCs; when these inhibitory receptors are blocked, a more uniform 
immune response against populations of both CSCs and non-CSCs may possibly be 
achieved, resulting in long-term responses.
Exploiting metabolic differences to target CSCs
The field of cancer metabolism has undergone a revival over the past decade with renewed 
interest in the Warburg effect, which proposes that cancer cells generate ATP through 
glycolysis rather than oxidative phosphorylation, doing so even under non-hypoxic 
conditions130. Through several key breakthrough studies, the role of cell metabolism has 
evolved into an active area of cancer research with the development of novel therapeutics 
based on our understanding of the signaling regulating metabolic pathways 131, including 
temsirolimus and everolimus, inhibitors of mTORC1, which are approved to treat several 
cancers132–139.
Hypoxia within a tumor can lead to alterations in the metabolism of cancer cells through the 
inhibition of mTOR signaling140. The hypoxic conditions that are apparent in many if not 
most tumors have also been shown to lead to the induction of an EMT and the generation of 
CSCs141, 142. This leads to the speculation that hypoxia-induced metabolic changes could 
contribute to the mesenchymal/CSC phenotype. Indeed, a recent study reported a metabolic 
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switch to glycolysis that occurs upon activation of the EMT-inducing transcription factor 
Snail and that blocking of this switch through ectopic expression of fructose-1,6-
biphosphatase (FBP1) abrogates the ability of Snail to impart mesenchymal/stem-like 
properties to breast cancer cells143. Other studies also show the components of the 
mevalonate metabolic pathway to be important in the generation of breast CSCs, with 
inhibition of the pathway using hydroxy-3-methylglutaryl CoA reductase blockers, resulting 
in reduction of CSC properties144. These studies suggest that alteration of the metabolic 
phenotype could be an essential step required for entrance into the CSC state, and that study 
of the differences in metabolism between CSCs and non-CSCs may reveal novel ways by 
which we can specifically target these cells.
Conclusions
The avenues discussed above represent only a portion of the possible ways by which CSCs 
could be targeted therapeutically. For example, another strategy that has not been discussed 
here involves the delivery of short-hairpin or small-interfering RNAs that can induce a CSC-
specific knock-down of critical genes identified through large-scale screening. Synthetic 
lethality studies might also uncover novel dependencies of CSCs that could be candidates 
for future targeting studies.
There are, however, multiple hurdles that have to be surmounted before we can effectively 
eliminate these cells. First, it is apparent that CSCs exists in a specific niche formed by 
multiple cell types and distinct signaling molecules, including growth factors, cytokines and 
ECM components. Hence, studying the biological properties of CSCs in isolation or 
performing screens with them in the absence of a surrounding relevant niche is hardly 
guaranteed to yield results that can be translated to responses occurring in vivo. Second, our 
lack of appropriate experimental systems to accurately model human tumors means that, at 
least at present, we are forced to study human tumors in immunodeficient mice in the 
absence of an adaptive immune system or study mouse tumors in a syngeneic setting. 
Neither of these experimental settings accurately recapitulates the biological complexity of 
the tumors encountered in the oncology clinic.
The current practice of modeling human tumors by the alteration of one or two genetic loci 
in the cells of mice cannot provide a fair representation of the intricate nature of the disease 
and may not lead to the development of therapies that translate directly humans. Moreover, 
mouse and human cells have fundamental differences in their intracellular wiring, which 
lead to differences in the processes underlying tumorigenesis in these two species145 . 
Hence, we need to devise novel and appropriate ways to study primary human tumor 
xenografts in ways that preserves their CSC subpopulations in physiologic states similar to 
those that existed prior to the isolation from patients. The use of mice that harbor a human 
immune system (humanized mice146) may partly compensate for the lack of an adaptive 
immune system; for example, the macrophages that home to tumors growing as xenografts 
in such mice would be of human origin, secreting factors that may serve to model a CSC 
niche more similar to the one found in the human body. Ultimately, using better models, we 
should be able to develop a more detailed, nuanced understanding of the essential nature of 
CSCs and the mechanisms supporting them within human tumors.
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BOX 1
A brief history of modern CSC research
The field of CSC research was first launched by the experimental demonstration that 
certain minority subpopulations of primary human acute myeloid leukemias (AML) 
could propagate disease in immunodeficient mouse hosts at higher frequencies than the 
bulk populations of leukemic cells forming these neoplasms151. These leukemia-
initiating cells were studied when grown as xenografts in severe combined 
immunodeficient (SCID) mouse hosts, and as such, were termed SCID leukemia-
initiating cells. They were found to exhibit cell-surface antigen marker phenotypes 
similar to those of normal SCID-repopulating cells, implying that the cell-of-origin for 
this disease was closely allied to a hematopoietic stem cell240. These observations led, 
over the ensuing decade, to hunts for corresponding CSCs in solid tumors, resulting in 
the discovery of such populations in breast20, 28, brain11, prostate14, ovarian241, colon 
155, 176, 177, liver13, 158, lung12 and pancreatic tumors13. In each case, these CSC 
subpopulations, which usually exist as minority subpopulations within tumors, have been 
defined operationally by their elevated tumor-initiating ability relative to that of 
corresponding majority populations of neoplastic cells in various tumors (Fig 1).
Despite repeated successes in identifying such tumor-initiating subpopulations of cells 
within individual tumors, there has been substantial skepticism and controversy arising 
from the fact that these repopulation studies were carried out in immunocompromised 
mice, which lack an adaptive immune system and whose tissue microenvironments may 
therefore differ substantially from those present in humans242. Additionally, studies in 
several cancers, such as AML and melanoma, have shown that CSCs need not be rare 
subpopulations and could be as frequent as 1 in 4 cells 119, 243. It is now well accepted 
that certain types of cancer, such as melanoma, do not closely follow the CSC paradigm 
developed from studying carcinomas, whereas many others, such as breast cancer, do 
indeed do so. Moreover, studies in genetically engineered mouse models (GEMMs) have 
also demonstrated the presence of CSCs in certain leukemias and breast cancer, 
providing direct support for the CSC model in syngeneic models 244, 245.
More recently, three lineage-tracing studies have provided unequivocal evidence of the 
existence of CSCs in syngeneic models of authochthonously arising tumors. One group 
used a GEMM that expresses ΔTK-IRES-GFP transgene driven by the promoter of the 
Nestin gene that is normally expressed in neural stem cells; this transgene ensured 
expression of both the thymidine kinase (TK) and green fluorescent proteins in stem 
cells. Upon crossing these Nes-ΔTK-GFP mice with a GEMM strain engineered to 
develop glioblastomas at high rates (Mut7 mice), the authors observed the presence of a 
minor quiescent GFP+ subpopulation. Moreover, upon treatment with a 
chemotherapeutic agent, temozolomide (TMZ), the bulk of the highly proliferative GFP- 
compartment in each tumor was eliminated, resulting in the preferential survival of the 
GFP+ CSCs, which expanded thereafter to give rise to a relapsed tumor 37. This ability 
of the tumors to regrow following TMZ treatment was lost upon treatment with 
ganciclovir, which eradicated those cells expressing the TK gene, i.e., the Nestin-
expressing tumor-initiating population.
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A different strategy was followed by a second group, which employed a GEMM that 
expresses yellow-fluorescent protein (YFP) in the keratin-14-expressing cells of the basal 
layer of the skin epidermis, doing so conditionally in response to Cre-mediated 
recombination. This labeling strategy was used to trace carcinogen-induced squamous 
skin papillomas, revealing that the bulk of such tumors had limited proliferative capacity. 
However, ~20% of cells possessed the capacity for long-term propagation and were 
capable of giving rise to progeny that constituted the majority of the tumor. This 
indicated that a subset of the tumor cells, the CSCs, were capable of generating the bulk 
of the tumor, ostensibly by undergoing asymmetric division. During the transition from a 
benign papilloma to a more malignant squamous cell carcinoma, an increase in the 
numbers of these long-term replicating CSCs was accompanied by a concurrent decrease 
in the number of differentiated cells. The increase in proportion of CSCs correlates with 
the increase in aggressiveness of the tumor upon transition to a full-blown carcinoma246.
A small population of Lgr5+ cells residing in the intestinal crypt has been found to have 
the potential to divide both symmetrically and asymmetrically and has previously been 
identified as the stem cell in this organ247. Quite recently, a third group employed Lgr5-
specific Apc mutant mice; in these mice, the Apc mutation leads to aberrant activation of 
the Wnt pathway specifically in Lgr5-expressing intestinal stem cells. These mice were 
crossed with multicolor Cre reporter mice in which activation of Cre recombinase, by 
administration of tamoxifen, enables single Lgr5+ stem cells to randomly adopt one of 
four alternative fluorescent labels. This led to the formation of single-colored tumors that 
consisted of several cell types, indicative of the presence of individual Lgr5+ CSCs, each 
of which could give rise to a tumor containing several distinct cell types. Additionally, 
when a second low dose of tamoxifen was administered, a few of the Lgr5+ CSCs 
changed to a different color following a pulse of Cre activation. This gave rise to a 
stream of cells in the newly displayed color, showing that these CSCs were consistently a 
source that could replenish the bulk of cells in each of the observed adenomas 248.
These studies have verified the existence of CSCs in three different tumor models, 
eliminating major doubts about the existence of such populations within the syngeneic 
tumor microenvironments of autochthonously arising tumors. Moreover, these studies 
provided compelling evidence that such CSCs adhere to the stem-cell model by self-
renewing and at the same time generating progenitors that have lost their stemness and 
proceed to form the bulk of a tumor.
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BOX 2
How do CSCs arise?
Carcinomas usually arise as a consequence of a succession of genetic and epigenetic 
alterations occurring over many years if not decades; the accumulation of these changes 
leads ultimately to expression of the multiple neoplastic traits associated with highly 
malignant cells and thus aggressive tumors. This raises the question of whether CSCs are 
invariably present within incipient tumors at these various stages of tumor progression. 
One insight – nothing more than a speculation at present – comes from the observed 
similarities between normal tissue SCs and CSCs cited above: If the cells in fully normal 
epithelial tissues existing prior to tumor initiation contain subpopulations of SCs, and if 
progressed, highly malignant populations of carcinoma cells arising at the last step of 
tumor progression contain SCs (i.e., CSCs), then it seems plausible that each of the cell 
populations formed at intermediate stages of tumor progression also contains its own 
subpopulation of SCs. Stated in a more general way, all populations of epithelial cells, 
independent of their stage of tumor progression, may contain subpopulations of SCs. 
Indeed, this may even hold true for populations of epithelial cells propagated in vitro.
If SCs of various genetic configurations were to be found to be present at all of the 
distinct stages of multi-step tumor progression, this would seem to suggest, in turn, that 
each SC subpopulation derives directly from a SC subpopulation existing in the previous 
stage of tumor progression, i.e., one SC subpopulation evolves directly into the SCs 
present in the successor subpopulation driving growth of the next, incrementally more 
aggressive stage of tumor progression. Although attractive for its simplicity, this model 
carries with it several biological problems, including the fact that SCs, including CSCs 
represent relatively small target populations that generally are not highly active 
mitotically. Given this, a more plausible model is that transit-amplifying/progenitor cells 
are the targets of mutation during multi-step tumorigenesis, and that they introduce their 
acquired mutations into corresponding SC pools via a process of spontaneous 
dedifferentiation73, 74.
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BOX 3
What constitutes the tumor microenvironment?
The tumor microenvironment, in addition to harboring carcinoma cells, consist of various 
components that play a major role in influencing the outcome of the malignancy. These 
can be widely classified into three main groups – cells of hematopoietic origin, cells of 
mesenchymal origin and non-cellular components. Tumors of different origins and 
different stages of progression will inevitably contain components in various proportions. 
Nonetheless, these three classes of stromal components represent the most abundant 
elements present in the microenvironment of solid tumors.
Cells of hematopoietic origin
This compartment consists of cells that arise in the bone marrow and can be subdivided 
into cells of the lymphoid lineage consisting of T-cells, B-cells and NK-cells, and those 
of the myeloid lineage that include macrophages, neutrophils and myeloid-derived 
suppressor cells (MDSC). The roles of different subsets of T-cells in tumor 
promotion249 and tumor elimination250 have been well studied and are the subject of 
recent advances in the development of novel immunotherapies126. The alternate 
activation of macrophages and their ability to promote tumor development and 
progression have also been well documented251. Similarly, each of the other constituent 
cell types has either a positive or negative effect on the outcome of the tumor. 
Importantly, interactions between different cell types within the stroma can also play a 
major role on tumor progression, as has been shown for CD4+ T cells and 
macrophages252, for example. Other cell types that play a major role in tumorigenesis 
but are not abundantly present in the tumor microenvironment per se include platelets 
and dendritic cells.
Cells of mesenchymal origin
These comprise of cells derived from the mesenchyme and include fibroblasts, 
myofibroblasts, mesenchymal stem cells (MSCs), adipocytes and endothelial cells. 
Myofibroblasts and MSCs derived from the bone marrow have been shown to directly 
support CSCs by creating a favorable niche and facilitating tumor progression78, 253. 
Adipocytes, until recently were thought of only as energy storage houses; however, 
recent studies reveal the importance of factors that they secrete (e.g., hepatocyte growth 
factor; HGF) in tumor progression254. Endothelial cells and pericytes that constitute the 
walls of blood vessels play a major role in vascular functionality, angiogenesis as well as 
regulating cancer cell dissemination.255
Non-cellular components
The major non-cellular component of the tumor microenvironment is the extracellular 
matrix (ECM), which consists of many distinct components including proteins, 
glycoproteins and proteoglycans that enable its functions both structurally and 
functionally77. The ECM can be subdivided into the more compact basement membrane, 
which is a specialized ECM rich in type IV collagen, laminin and fibronectin, and the 
interstitial matrix, which consists of fibrillar collagens, proteoglycans and glycoproteins 
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that contribute to the tensile strength of the tissue77.The ECM is involved in the 
formation of a SC niche and while it acts to maintain tissue architecture and prevent 
cancer cell invasion, abnormal ECM has been shown to promote tumor progression and 
tumor angiogenesis77.
Together these components make up the tumor microenvironment, which represents a 
complex habitat involving myriad interactions between cell types and ECM, each of them 
playing a role in influencing tumor outcome.
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Figure 1. 
Why specific targeting of CSCs is important. (A) Why specific targeting of CSCs is 
important: Two major issues confound our ability to treat cancers – their ability to resist 
cytotoxic therapy and their propensity to form metastases. Tumors are a heterogeneous 
mixtures of epithelial cells that consist of CSCs that have mixed epithelial-mesenchymal 
phenotypes and non-stem cells which are epithelial. Carcinoma cells may also be able to 
undergo a complete EMT, generating cells that resemble stromal-like fibroblasts and 
mesenchymal stem cells that may create a permissive niche. (B) The use of specific 
inhibitors of CSCs would attenuate their ability to survive conventional cytotoxic therapies 
and relapse. Loss of the mesenchymal/CSC population would also retard metastatic spread 
of the tumor.
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Figure 2. 
Signaling pathways employed by CSCs: Distinct combinations of paracrine and juxtracrine 
signals induce the EMT in different contexts. A representation of signaling pathways that 
CSCs have been reported to depend on is shown here. The transcription factors that are 
downstream of these signaling pathways act as co-factors and cooperate with the EMT-
inducing transcription factors such as Snail to induce and maintain the mesenchymal/CSC 
state. The EMT program also activate several positive, self-reinforcing feedback loops in 
order to maintain cells in a mesenchymal/CSC state; shown here are three involving 
canonical and non-canonical Wnts as well as TGF-β. Nodes of the pathway that could be 
open to therapeutic targeting are indicated by red arrowheads.
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Figure 3. 
Impact of stromal cells and secreted factors on CSCs – Each stromal cell type depicted here 
influences the tumor by secreting factors that stimulate the formation of CSCs and help 
maintain the residence of already-formed CSCs in the SC state. Summarized here are some 
of the major factors that secreted by each cell type that are known to impact CSCs. Green 
arrow – Tumor promotion, Red crossbar – Tumor inhibition.
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Figure. 
Illustration of tumor microenvironment showing all major constituents mentioned above
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Table 1
List of commonly used CSC markers, their expression and function in normal tissue
Marker Expression in normal
tissue
Normal Function Reported to be CSC marker in
CD34 Hematopoietic stem and
progenitors147,148, endothelial
cells149
Regulator of cell adhesion150 Hematological malignancies in
combination with CD38151
CD38 Hematopoietic cells, skelet al
and heart muscle, proximal
convoluted tubules of
kidney, normal adult
prostate152
Ecto-enzyme involved in
signal transduction, calcium
signaling and cell
adhesion152
Hematological malignancies in
combination with CD34151
CD44 Leukocytes, epithelial cells,
Endothelial cells,
mesenchymal cells153
Varied functions including
cell adhesion and migration,
cell-cell interaction, cell
signaling, leukocyte
attachment and rolling154
Breast in combination with CD2428,
Colon in combination with
EpCAM155Gastric156Head and
Neck157Liver in combination with
CD90158Ovarian in combination
with c-Kit158Pancreatic in
combination with EpCAM and
CD24159Prostate in combination
with integrin α2β1 and CD13314
CD24 B cells, follicular dendritic
cells, granulocytes, epithelial
cells160
B-cell proliferation and
maturation160. Function in
other tissue is poorly
understood.
Breast28, Gastric in combination
with CD44161Pancreatic in
combination with EpCAM and
CD44159
CD90 Fetal liver cells and
thymocytes162, hematopoietic
stem and progenitor cells163
mesenchymal stromal
cells164, activated endothelial
cells165, neuronal cells166
Regulation of cell
adhesion167, signal
transduction in T cells168
Brain169Liver170 and Lung
tumors171
CD133 Hematopoietic stem and
progenitor cells172
endothelial progenitor
cells173, fetal neural stem
cells174, renal stem cells16
prostate stem cells18
Poorly understood Brain175Colon176,177
Endometrial178Liver179Lung with
ABCG2 or CXCR4180Ovarian181
Pancreatic in combination with
CXCR413Prostate in combination
with integrin α2β1 and CD4414
ALDH Epithelial cells of the
esophagus, stomach,
intestine, colon, liver,
mammary gland and
pancreas. Endocrine cells of
the adrenal, thyroid and
salivary glands,
haematopoietic cells182.
Conversion of aldehydes
generated by metabolic
processes into carboxylic
acids183. Function in ester
hydrolysis and as an
antioxidant184. Involved in
retinoic acid signaling184.
Breast20Colon185Head and
Neck186Liver in combination with
CD13322Melanoma187 and
Pancreatic tumors
Hoechst33342
exclusion
(Side
population)
Hematopoietic stem cells25
mammary stem/progenitor
cells188,189, pulmonary stem
cells190, cardiac
Not an endogenous
marker/protein, but based on
the ability of cells to efflux
Hoechst33342 involving the
Astrocytomas195Gastrointestinal
tumors196Gliomas197
Hepatocellular carcinomas198Lung
cancer199Thyroid cancer200
progenitors191, hepatocyte
progenitors192, neural stem
and progenitors193 and
keratinocytes progenitors194.
ABC transporter trans-
membrane proteins25.
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Table 2
List of pathways that may be beneficial for the specific targeting of CSCs and potential candidates in clinical 
development
Pathway Targets Compounds Potential Indications Clinical development
Wnt Porcupine IWP95
or
LGK97496
Breast cancer – Maintenance of
breast CSCs through 
recruitment
of Wnt ligands201
Phase I trial for malignancies
dependent on Wnt ligands
including melanoma, breast
and pancreatic malignancies
http://clinicaltrials.gov/show/NCT01351103
Pancreatic cancer – Circulating
tumor cells show high levels of
WNT2 expression202
β-catenin: -
Interaction of β-
catenin with TCF,
CBP
- Tankyrase
inhibition for
stabilization of
AXIN2
ICG-00194
or
iCRT203
or
OXT-328204
or
XAV-939205
or
IWR95
Colon cancer – Required for
maintenance of Colon CSCs
through signals from stroma30
CWP232291206 which induces
β-catenin degradation is under
Phase I trials for AML and
CML
http://clinicaltrials.gov/ct2/show/NCT01398462
Phase I trials for advanced
solid tumors
http://clinicaltrials.gov/ct2/show/NCT01302405
AML and CML – Could prove
effective in MLL-fusion driven
AML CSCs and Imatinib
resistant CSCs in CML207,208
Breast cancer – Degradation of
β-catenin blocks the generation
of breast CSCs204
Squamous cell carcinoma – β-
catenin required for 
maintenance
of CSCs and tumor
progression209
TGF-β TGF-βRI LY2157299210 Breast cancer – Increased TGF-
β signaling in CSCs of
chemotherapy-resistant breast
cancer122
LY2157299 in Phase I trials
for recurrent malignant
glioma
http://clinicaltrials.gov/ct2/show/NCT01682187
Glioma – Inhibition of TGF-β
decreases glioma-initiating cell
population211
Pancreatic cancer - TGF-β
induces an EMT in CSCs
promoting metastasis212
TGF-β GC1008213
a.k.a.
Fresolimumab
or
AP12009214
As above Phase I trial of GC1008 in
Glioma
http://clinicaltrials.gov/ct2/show/NCT01472731, 
Renal cell
carcinoma and Melanoma
http://clinicaltrials.gov/ct2/show/NCT00356460 
and
metastatic breast cancer
http://clinicaltrials.gov/ct2/show/NCT01401062
Phase I trial of AP12009 in
Melanoma, Pancreatic and
Colorectal neoplasms
http://clinicaltrials.gov/ct2/show/NCT00844064
NOTCH Gamma-secretase MK-0752215
or
PF03084014216
or
R04929097217
Breast cancer – NOTCH
signaling regulates breast
CSCs218
Phase I trial of MK-0752 in
advanced breast cancer
http://clinicaltrials.gov/ct2/show/NCT00106145
Phase I trial of PF-03084014
in metastatic breast cancer
http://clinicaltrials.gov/ct2/show/NCT01876251 
and glioma
Phase I trial of R04929097 in
advanced solid tumors217
Ovarian cancer – NOTCH
signaling is critical for the
regulation of CSCs and 
platinum
resistance219
Glioblastoma – CSCs receive
NOTCH signals from
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Pathway Targets Compounds Potential Indications Clinical development
endothelial cells in stroma220
Pancreatic cancer – NOTCH
inhibition induces apoptosis in
pancreatic CSCs221
DLL4 Anti-DLL4
Ab106, 222
Colon cancer – Blocking DLL4
reduces tumor-initiating
frequency106
Phase I trial of MEDI0639 in
advanced solid tumors
http://clinicaltrials.gov/ct2/show/NCT01577745
Hedgehog SMO Cyclopamine22
3
 or
GDC-0449224
or
LDE225225
Glioblastoma – Self-renewal of
CSCs requires Hh-Gli
signaling226,227
Phase I trial of LDE225 in
advanced solid tumors
http://clinicaltrials.gov/ct2/show/NCT01576666
Phase I trial of a combination
of NOTCH and SMO
inhibition in metastatic breast
cancer
http://clinicaltrials.gov/ct2/show/NCT01071564
Breast cancer – Hh signaling
regulates self-renewal of breast
CSCs52
Pancreatic cancer – Hh
inhibition reverses the EMT 
and
tumor metastasis228
CML – Expansion of LSCs is
dependent on activation of 
Hh229
Multiple myeloma – Hh
signaling important for
maintenance of CSCs230
JAK-
STAT
IL-6 CNT0328231
or
Tocilizumab232
AZD1480233
Compound1234,235
Glioblastoma – STAT3 
required
for multipotency of CSCs236
Phase II trial of CTN0328 in
advanced prostate cancer
http://clinicaltrials.gov/ct2/show/results/
NCT00433446
Phase I trial of OPB-31121 in
advanced solid tumors
http://clinicaltrials.gov/ct2/show/study/
NCT00955812
Phase I trial of WP1066 in
glioblastoma and other solid
tumors
http://clinicaltrials.gov/ct2/show/NCT01904123
Colon cancer – STAT3 
required
for survival and proliferation of
CSCs237
JAK1/2 Prostate cancer – Blockade of
JAK-STAT pathway inhibits
CSC function238
STAT3 Breast cancer – JAK-STAT
pathway required for breast 
CSC
signaling82
PDGFR PDGFR/PKCα Bisindolylmal
eimide I239
Breast cancer – PDGFR
signaling required for survival
of breast CSCs54
Phase II trial of ISIS 3521 in
metastatic breast cancer
http://clinicaltrials.gov/ct2/show/NCT00003236
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